Latest Press Releases

OPEN Health Appoints Matt D'Auria as Chief Executive Officer to Drive Innovation and Growth

London, March 31, 2025 (GLOBE NEWSWIRE) -- March 31, 2025, London, UK - OPEN Health Group is pleased to announce the appointment of Matt D'Auria as its new Chief Executive Officer (CEO). Based in the US, Matt brings more than 25 years of ...

Modern Aminos: 7 Essential Trends in Aminos Research

Modern Aminos: Pioneering Aminos Research in Scientific Innovation Modern Aminos leads the way in scientific exploration. In our research lab, Aminos Research takes center stage as we analyze compounds with precision. Our focus is on ...

CBD Edibles Vs. Capsules What Is Right for Me?

Nowadays, there are many CBD products available on the market, with some of the most popular being CBD capsules and edibles . If you think about starting using CBD to see if it can improve your health and wellbeing, you might be wondering if ...

Amaran Biotech Wins "Best CDMO in Automated Aseptic Filling"

TAIPEI, Taiwan, March 27, 2025 (GLOBE NEWSWIRE) -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), was honored with the "Best CDMO in Automated Aseptic Filling" award at the Taiwan Biopharma ...

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

PR Newswire CRANBURY, N.J., March 31, 2025 CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the ...

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

PR Newswire NEW YORK, March 31, 2025 NEW YORK, March 31, 2025 /PRNewswire/ -- Transcend Therapeutics, a clinical-stage biotechnology company that develops medicines to treat neuropsychiatric diseases, today announced positive results from ...

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

PR Newswire SOUTH SAN FRANCISCO, Calif., March 31, 2025 SOUTH SAN FRANCISCO, Calif., March 31, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Modern Aminos: 7 Essential Trends in Aminos Research

Modern Aminos: Pioneering Aminos Research in Scientific Innovation Modern Aminos leads the way in scientific exploration. In our research lab, Aminos Research takes center stage as we analyze compounds with precision. Our focus is on ...

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma

PR Newswire SAN FRANCISCO and SUZHOU, China, March 30, 2025 SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, ...

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels

PR Newswire INDIANAPOLIS, March 30, 2025 In Phase 2 ALPACA results, lepodisiran significantly reduced levels of genetically inherited cardiovascular risk factor, with some patients sustaining reductions for nearly 1.5 years These data ...

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

PR Newswire GALWAY, Ireland and CHICAGO, March 30, 2025 GALWAY, Ireland and CHICAGO, March 30, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced late-breaking data on five-year outcomes ...

Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

PR Newswire SINGAPORE and PRINCETON, N.J., March 27, 2025 SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 27, 2025 /PRNewswire/ -- ...

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight

PR Newswire LAS VEGAS, March 27, 2025 With the emergence of novel therapies and expanded indications, the United States IL-2 market is projected to reach USD 4 billion by 2034. Key players driving this expansion include Iovance ...

Alzheimer's Early Detection Tests Using Video Games Could Be As Effective as Blood Tests and Boost Clinical Trials

PR Newswire NEWARK, N.J., March 27, 2025 Tests Were Created by Rutgers-Newark Researchers NEWARK, N.J., March 27, 2025 /PRNewswire/ -- Alzheimer's early detection tests using video games developed by Rutgers University–Newark researchers ...

Obesity Action Coalition Launches "Imagine a World Without Weight Stigma" Creative Contest Honoring 20th Anniversary

PR Newswire TAMPA, Fla., March 27, 2025 TAMPA, Fla., March 27, 2025 /PRNewswire/ -- To commemorate its 20th Anniversary in 2025, the Obesity Action Coalition (OAC) is excited to announce the launch of the "Imagine a World Without Weight ...

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

PR Newswire DUBLIN, March 27, 2025 – Survey Respondents Reported That Medication Adherence is a Top Concern for Healthcare Providers When Selecting Treatments and Frequent Medication Switches Can Have Significant Impacts on Patients' ...

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

PR Newswire SAN DIEGO, March 27, 2025 Positive Topline Data from the Fourth Cohort of Patients Consistent demonstration of polycystin (PC) biomarker impact confirming 300 mg fixed dose selection to achieve optimal kidney exposure ...

New Data Reveals Escalating Anxiety Among Canadians Amid Political and Economic Turmoil - GreenShield Responds with Free Therapy Initiative to Support All Canadians

Canada NewsWire TORONTO, March 27, 2025 GreenShield, Canada's only national non-profit health and benefits provider, offering no-strings-attached two months of free therapy to Canadians looking to start their mental health journey. ...

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

PR Newswire DUBLIN, March 27, 2025 DUBLIN, March 27, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today announced new analyses of the initial Phase 3 program of ampreloxetine ...

Micropos Medical: Precision Study Underway - 100 Prostate Cancer Patients Treated in Just Three Radiation Sessions

PR Newswire GOTHENBURG, Sweden, March 27, 2025 GOTHENBURG, Sweden, March 27, 2025 /PRNewswire/ -- Last week the Edinburgh Cancer Centre begun treating prostate cancer patients within the framework of the so-called Precision Study. Patients ...

JOMS study: Viewing social media increases anxiety before wisdom teeth surgery

PR Newswire ROSEMONT, Ill., March 27, 2025 A new study published in the March issue of the Journal of Oral and Maxillofacial Surgery (JOMS) – the official peer-reviewed journal of the American Association of Oral and Maxillofacial Surgeons ...

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

PR Newswire BOSTON and LAUSANNE, Switzerland, March 27, 2025 BOSTON and LAUSANNE, Switzerland, March 27, 2025 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immune-dermatology focused company, today announces that the first patient ...

CBD Edibles Vs. Capsules What Is Right for Me?

Nowadays, there are many CBD products available on the market, with some of the most popular being CBD capsules and edibles . If you think about starting using CBD to see if it can improve your health and wellbeing, you might be wondering if ...

New Report Measures States' Preparedness for Public Health Emergencies, Including Infectious Disease Outbreaks and Extreme Weather Events

PR Newswire WASHINGTON, March 27, 2025 Special Feature Examines the Threat of H5N1 Bird Flu and How to Guard Against Its Spread WASHINGTON, March 27, 2025 /PRNewswire/ -- A new report assessing national and state preparedness to protect ...

UT Health San Antonio-led research discovers a way to slow or block recurrence of glioblastoma

PR Newswire SAN ANTONIO, March 26, 2025 Research led by The University of Texas Health Science Center at San Antonio identifies a means of blocking recurrence of glioblastoma, the deadliest brain cancer. SAN ANTONIO, March 26, 2025 ...

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

PR Newswire BASEL, Switzerland, March 26, 2025 Results from Phase 2a Trial demonstrate a good safety and tolerability profile of VXM01 and Avelumab Combination Therapy in Glioblastoma, supporting further investigation of VXM01 BASEL, ...

Mediaplanet and Dave Coulier Raise Awareness on Blood Health

PR Newswire NEW YORK, March 26, 2025 NEW YORK, March 26, 2025 /PRNewswire/ -- Today Mediaplanet announces the launch of Blood Health, designed to raise awareness of blood disorders, cancers, and bleeding disorders. This wide-reaching ...

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

PR Newswire SAN DIEGO, March 26, 2025 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily Results Expected in 2H25 SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: ...

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

PR Newswire CAMBRIDGE, Mass., March 26, 2025 Updated data confirms statistically significant 32% higher ORR and 3.5 month longer PFS in second-line CRC patients with high DKK1 levels treated with sirexatamab plus bevacizumab and chemotherapy ...

Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy

PR Newswire TAIPEI, March 26, 2025 TAIPEI, March 26, 2025 /PRNewswire/ -- Yoda Therapeutics Inc. (YODA), an AI-driven company that focuses on Central Nervous System (CNS) drugs, today announced the dosing of the first patient in the Phase 2 ...

Medical researchers develop a fresh theory about what makes infants most at risk of Sudden Infant Death Syndrome

PR Newswire REDMOND, Wash., March 26, 2025 REDMOND, Wash., March 26, 2025 /PRNewswire/ -- Research conducted as part of a unique partnership between the Center for Integrative Brain Research at Seattle Children's and data scientists at ...

NUS researchers develop microneedle technology to accelerate diabetic wound healing

PR Newswire SINGAPORE, March 26, 2025 'Sponge-like' microneedle patches deliver bioactive ingredients and reduce inflammation in slow- and non-healing wounds SINGAPORE, March 26, 2025 /PRNewswire/ -- Diabetic wounds often lead to severe ...

Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

PR Newswire CHENGDU, China, March 25, 2025 CHENGDU, China, March 25, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company has received a clinical trial notice approving the ...

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

PR Newswire BOSTON, March 25, 2025 -- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell ...

Latest Press Releases

Premium Press Releases »

OPEN Health Appoints Matt D'Auria as Chief Executive Officer to Drive Innovation and Growth

Modern Aminos: 7 Essential Trends in Aminos Research

CBD Edibles Vs. Capsules What Is Right for Me?

Amaran Biotech Wins "Best CDMO in Automated Aseptic Filling"

Press Releases »

Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study

Transcend Therapeutics Announces Primary Endpoint Met in IMPACT-1 Phase 2 Study of TSND-201 in PTSD

IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma

Modern Aminos: 7 Essential Trends in Aminos Research

Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2a-bias Bispecific Antibody Fusion Protein) in Melanoma

Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels

Medtronic Evolut™ TAVR system shows durable clinical outcomes and outstanding valve performance at five years in low-risk aortic stenosis patients

Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2 Targeting Fusion Proteins, Monoclonal antibodies, and Gene Therapies Across Immunology, Dermatology, Neurodegenerative Disorders, and Oncology | DelveInsight

Alzheimer's Early Detection Tests Using Video Games Could Be As Effective as Blood Tests and Boost Clinical Trials

Obesity Action Coalition Launches "Imagine a World Without Weight Stigma" Creative Contest Honoring 20th Anniversary

New National Survey of Healthcare Providers Offers Insights Into the Dynamic and Challenging Treatment Journey for People Living With Schizophrenia or Bipolar I Disorder

Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

New Data Reveals Escalating Anxiety Among Canadians Amid Political and Economic Turmoil - GreenShield Responds with Free Therapy Initiative to Support All Canadians

Theravance Biopharma to Present New Ampreloxetine Analyses in Neurogenic Orthostatic Hypotension (nOH) at the 77th Annual Meeting of the American Academy of Neurology

Micropos Medical: Precision Study Underway - 100 Prostate Cancer Patients Treated in Just Three Radiation Sessions

JOMS study: Viewing social media increases anxiety before wisdom teeth surgery

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata

CBD Edibles Vs. Capsules What Is Right for Me?

New Report Measures States' Preparedness for Public Health Emergencies, Including Infectious Disease Outbreaks and Extreme Weather Events

UT Health San Antonio-led research discovers a way to slow or block recurrence of glioblastoma

Vaximm AG, an OSR Company, Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma

Mediaplanet and Dave Coulier Raise Awareness on Blood Health

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity

Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study

Yoda Therapeutics Announces First Patient Dosed in Phase 2 Trial of YA-101 for Multiple System Atrophy

Medical researchers develop a fresh theory about what makes infants most at risk of Sudden Infant Death Syndrome

NUS researchers develop microneedle technology to accelerate diabetic wound healing

Kelun-Biotech's Radionuclide-Drug Conjugate (RDC) SKB107 Receives NMPA Approval For The Treatment of Bone Metastases in Solid Tumors

Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025

Medindia Newsletters